GSK
2 years ago ⋅ English ⋅ 8 min read
Newsroom
ViiV Healthcare announces US FDA approval of Triumeq PD, the first dispersible single tablet regimen containing dolutegravir, a once-daily treatment for children living with HIV

For media and investors only- The FDA approval of the first dispersible single tablet regimen containing dolutegravir increases age-appropriate treatment options for children living wit... Read More
GSK
2 years ago ⋅ English ⋅ 7 min read
Newsroom
ViiV Healthcare announces label update for its long-acting HIV treatment, Cabenuva (cabotegravir, rilpivirine), to be initiated with or without an oral lead-in period

For media and investors onlyUS FDA approval of updated label streamlines the initiation process for the first and only complete long-acting HIV treatment by allowing people to start dir... Read More
GSK
2 years ago ⋅ English ⋅ 13 min read
Newsroom
GSK to demonstrate its commitment to improving outcomes for patients with gynaecologic cancer at the 2022 SGO Annual Meeting

Issued: 15 March 2022, London UK- Data presentations will deepen understanding of the options Zejula (niraparib) and Jemperli (dostarlimab) bring in treating ovarian and endometrial can... Read More
GSK
2 years ago ⋅ English ⋅ 6 min read
Newsroom
GSK announces appointments to Designate Haleon Board

Demerger and listing of Haleon expected in July 2022For media and investors onlyGlaxoSmithKline plc (GSK) (LSE/NYSE: GSK) today announced the appointment of six directors to the designa... Read More
GSK
2 years ago ⋅ English ⋅ 4 min read
Newsroom
European Medicines Agency (EMA) accepts marketing authorisation application for daprodustat

For media and investors only- Submission for the treatment of anaemia of chronic kidney disease based on the ASCEND Phase III clinical trial programme, consisting of five trials that al... Read More
GSK
2 years ago ⋅ English ⋅ 16 min read
Newsroom
GSK introduces Haleon to investors

For media and investors onlyGlobal leader in consumer health set to be a newly independent company with focused strategy to deliver sustainable above-market growth and attractive return... Read More